Orexo has been granted a patent for a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder for transmucosal drug delivery, particularly for allergic reactions like anaphylaxis. The composition includes epinephrine and maltodextrin with a dextrose equivalent above 15. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical composition for nasal delivery of epinephrine
A recently granted patent (Publication Number: US11957647B2) discloses a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder containing epinephrine or its salt along with a carrier material comprising maltodextrin with a dextrose equivalent (DE) above 15. The composition may also include a disaccharide like lactose or trehalose, with specific weight ratios, and a sucrose ester. The particle size distribution of the powder is crucial, with specific parameters mentioned in the claims, and the composition is essentially free of water or contains less than 5% water.
Moreover, the patent also covers an amorphous spray-dried powder composition for nasal delivery, containing epinephrine or its salt, a carrier material combination of trehalose and maltodextrin 19DE, sucrose monolaurate, and minimal water content. The particle size distribution of this powder is also specified. The patent further includes nasal applicator devices for delivering the compositions to the nose, packaged in containers that prevent the ingress of atmospheric water. Methods of treatment for allergic reactions, including anaphylaxis, using the disclosed compositions and devices are also detailed in the claims, emphasizing specific dosage amounts of epinephrine for effective treatment. The patent aims to provide a novel and effective means of administering epinephrine for allergic reactions, especially anaphylaxis, through nasal delivery using specialized compositions and devices.
To know more about GlobalData’s detailed insights on Orexo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
